TLDR
IBRX stock fell about 18% on Monday after a busy round of company news.
Q3 net product revenue hit $48.7 million, up 53%, and nine-month revenue rose 92% to $143.6 million.
ANKTIVA plus BCG met its primary goal in Cohort A of the QUILT-2.005 trial.
Q3 net loss to common stockholders grew to $184.6 million from $67.3 million.
A supplemental BLA for BCG-naive patients is planned for Q4 2026.
ImmunityBio (IBRX) stock fell about 18% on Monday, even though the company put out a long list of upbeat updates . The drop landed on a day packed with good news.
ImmunityBio, Inc., IBRX
Third-quarter net product revenue came in at $48.7 million, up 53% from a year ago. For the first nine months of 2026, the total reached $143.6 million, a 92% jump.
The company ended September with $334.3 million in cash, cash equivalents and marketable securities. Its market cap sits near $9.15 billion.
ImmunityBio shared three announcements today:
· QUILT-2.005: ANKTIVA® plus BCG met the primary endpoint in Cohort A of the randomized BCG-naïve, high-grade NMIBC trial
· Israel Approval: ANKTIVA® plus BCG was approved for adults with BCG-unresponsive NMIBC with CIS, with or…
— ImmunityBio, Inc. (@ImmunityBio) November 9, 2026
Average daily trading volume is about 11.3 million. The latest analyst rating on IBRX is a Buy, with a $12 price target.
A Trial Win in Bladder Cancer
On Monday, ImmunityBio said ANKTIVA plus BCG hit its main goal in Cohort A of the QUILT-2.005 trial. The study enrolled 370 patients with BCG-naive, high-grade non-muscle invasive bladder cancer.
The combo beat BCG alone in patients with carcinoma in situ, with or without papillary tumors. The company called the improvement statistically meaningful.
Side effects matched those seen with BCG alone. No treatment-related deaths were reported.
Patients also kept their quality of life. The median duration of response has not been reached.
ImmunityBio says it is still on track to file a supplemental BLA with the FDA in the fourth quarter of 2026. That filing would cover ANKTIVA plus BCG in BCG-naive patients.
The FDA already approved a broader label on October 14. It now covers BCG-unresponsive disease with high-grade papillary-only tumors.
Israel also approved ANKTIVA with BCG for BCG-unresponsive disease with carcinoma in situ. That brings the total to 35 countries, and the first patients in Europe began treatment in November.
Costs and Losses Grew
Research and development spending rose to $71.5 million in the third quarter, up from $51.2 million a year earlier. Selling, general and administrative costs climbed to $54.0 million from $36.3 million.
Net loss to common stockholders hit $184.6 million, compared with $67.3 million in the prior-year quarter. The company tied the jump mainly to non-cash changes in the fair value of a related-party convertible note and warrant liabilities.
The post ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth appeared first on Blockonomi .
